Table 2 Baseline clinical characteristics for the studied population before matching
Characteristics | Short-time group (n = 432) | Long-time group (n = 992) | P value |
|---|---|---|---|
Age (years) | 68 ± 11 | 67 ± 13 | 0.16 |
Male sex (n,%) | 280 (64.7%) | 653 (65.8%) | 0.72 |
Diabetes mellitus (n,%) | 172 (39.7%) | 404 (40.7%) | 0.77 |
Hypertension (n,%) | 270 (62.4%) | 605 (61.0%) | 0.59 |
Current smoker (n,%) | 137 (31.8%) | 386 (38.9%) | 0.04 |
Hypercholesterolemia (n,%) | 270 (62.4%) | 659 (64.4%) | 0.16 |
Previous MI (n, %) | 30 (6.9%) | 62 (6.3%) | 0.64 |
Previous PCI (n, %) | 52 (12.1%) | 116 (11.7%) | 0.86 |
Prior coronary bypass surgery (n, %) | 5 (1.2%) | 8 (0.8%) | 0.55 |
Renal insufficiency (n, %) | 27 (6.3%) | 62 (6.6%) | 1.0 |
Left ventricular ejection fraction (%) | 43 ± 11 | 45 ± 13 | 0.01 |
EF < 40% (n, %) | 38 (21.9%) | 54 (19.8%) | 0.03 |
Peak troponin I (ng/ml) | 16.45 ± 1.52 | 15.58 ± 1.46 | < 0.0005 |
hs-CRP (mg/L) | 22.8 ± 3.3 | 23.4 ± 3.6 | < 0.0005 |
BNP (pg/mL) | 232 ± 24 | 268 ± 33 | < 0.0005 |
Radial Access (n, %) | 387 (89.5%) | 827 (83.4%) | < 0.0005 |
Targeted vessel (n, %) | |||
LM | 8 (1.9%) | 21 (2.1%) | 0.94 |
LAD | 145 (33.6%) | 351 (35.4%) | |
LCX | 108 (25.0%) | 249 (25.1%) | |
RCA | 170 (39.3%) | 369 (37.2%) | |
Saphenous vein graft | 1 (0.2%) | 2 (0.2%) | |
Lesion type (n, %) | |||
A | 81 (18.7%) | 186 (18.8%) | 0.91 |
B1 | 52 (12.1%) | 128 (12.9%) | |
B2 | 167 (38.7%) | 365 (36.7%) | |
C | 132 (30.5%) | 313 (31.6%) | |
Multivessel disease (n, %) | 91 (21.1%) | 218 (22.0%) | 0.73 |
Multivessel intervention (n, %) | 83 (19.2%) | 188 (18.9%) | 1.00 |
Multilesion intervention (n, %) | 124 (28.7%) | 287 (28.9%) | 0.94 |
Stent length (mm) | 24.1 ± 7.3 | 19.7 ± 6.8 | |
Stents ≥2 (n, %) | 188 (43.5%) | 360 (36.3%) | 0.01 |
Side-branch involvement (n, %) | 99 (23.0%) | 249 (25.1%) | 0.38 |
Calcification lesion (n, %) | 121 (28%) | 272 (27.4%) | 0.85 |
Total occlusion lesion (n, %) | 96 (22.2%) | 229 (23.1%) | 0.78 |
Usage of ticagrelor (n, %) | 186 (43.1%) | 407 (41.0%) | 0.75 |
Usage of glycoprotein IIb/IIIa inhibitors (n, %) | 135 (31.1%) | 317 (32.0%) | 0.80 |